169 related articles for article (PubMed ID: 16978199)
1. Cytokeratin profiles of male breast cancers.
Ciocca V; Bombonati A; Gatalica Z; Di Pasquale M; Milos A; Ruiz-Orrico A; Dreher D; Folch N; Monzon F; Santeusanio G; Perou CM; Bernard PS; Palazzo JP
Histopathology; 2006 Oct; 49(4):365-70. PubMed ID: 16978199
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
3. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
5. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
6. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
7. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
Ribeiro-Silva A; Ramalho LN; Garcia SB; Brandão DF; Chahud F; Zucoloto S
Histopathology; 2005 Nov; 47(5):458-66. PubMed ID: 16241993
[TBL] [Abstract][Full Text] [Related]
8. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
[TBL] [Abstract][Full Text] [Related]
10. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
11. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.
Rodríguez-Pinilla SM; Rodríguez-Gil Y; Moreno-Bueno G; Sarrió D; Martín-Guijarro Mdel C; Hernandez L; Palacios J
Am J Surg Pathol; 2007 Apr; 31(4):501-8. PubMed ID: 17414096
[TBL] [Abstract][Full Text] [Related]
12. Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.
Delgallo WD; Rodrigues JR; Bueno SP; Viero RM; Soares CT
Cytopathology; 2010 Aug; 21(4):259-66. PubMed ID: 19843143
[TBL] [Abstract][Full Text] [Related]
13. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
[TBL] [Abstract][Full Text] [Related]
14. Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer.
Stein T; Price KN; Morris JS; Heath VJ; Ferrier RK; Bell AK; Pringle MA; Villadsen R; Petersen OW; Sauter G; Bryson G; Mallon EA; Gusterson BA
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6872-9. PubMed ID: 16203777
[TBL] [Abstract][Full Text] [Related]
15. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
Hungermann D; Buerger H; Oehlschlegel C; Herbst H; Boecker W
BMC Cancer; 2005 Jul; 5():92. PubMed ID: 16050957
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas].
Liu N; Niu Y; Wang SL; Yu Q; Zhang RJ; Liu TJ
Zhonghua Yi Xue Za Zhi; 2010 May; 90(20):1403-7. PubMed ID: 20646630
[TBL] [Abstract][Full Text] [Related]
17. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
18. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?
Tang P; Wang J; Bourne P
Hum Pathol; 2008 Apr; 39(4):506-13. PubMed ID: 18289638
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma.
Ribeiro-Silva A; Ribeiro do Vale F; Zucoloto S
Am J Clin Pathol; 2006 Apr; 125(4):512-8. PubMed ID: 16627261
[TBL] [Abstract][Full Text] [Related]
20. Expression of luminal and basal cytokeratins in human breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell J; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
J Pathol; 2004 Jun; 203(2):661-71. PubMed ID: 15141381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]